

Stavros V Konstantinides

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/650591/publications.pdf>

Version: 2024-02-01

373
papers

39,803
citations

7069

78
h-index

2883

190
g-index

419
all docs

419
docs citations

419
times ranked

32068
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
2	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	1.0	2,645
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
4	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426
5	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
6	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	13.9	1,221
7	Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2002, 347, 1143-1150.	13.9	947
8	Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism: Results of a Multicenter Registry. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1165-1171.	1.2	936
9	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	3.1	806
10	Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2363-2371.	1.1	659
11	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	2.9	455
12	Association Between Thrombolytic Treatment and the Prognosis of Hemodynamically Stable Patients With Major Pulmonary Embolism. <i>Circulation</i> , 1997, 96, 882-888.	1.6	403
13	Importance of Cardiac Troponins I and T in Risk Stratification of Patients With Acute Pulmonary Embolism. <i>Circulation</i> , 2002, 106, 1263-1268.	1.6	398
14	Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2015, 36, 605-614.	1.0	382
15	A Comparison of Surgical and Medical Therapy for Atrial Septal Defect in Adults. <i>New England Journal of Medicine</i> , 1995, 333, 469-473.	13.9	380
16	Patent Foramen Ovale Is an Important Predictor of Adverse Outcome in Patients With Major Pulmonary Embolism. <i>Circulation</i> , 1998, 97, 1946-1951.	1.6	379
17	Management of venous thrombo-embolism: an update. <i>European Heart Journal</i> , 2014, 35, 2855-2863.	1.0	355
18	Thrombosis: a major contributor to the global disease burden. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1580-1590.	1.9	343

#	ARTICLE	IF	CITATIONS
19	Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. <i>European Heart Journal</i> , 2015, 36, 1405-1414.	1.0	324
20	Thrombolysis during cardiopulmonary resuscitation should be addressed in guidelines for pulmonary embolism: reply. <i>European Heart Journal</i> , 2008, 29, 3067-3068.	1.0	313
21	Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. <i>Journal of Clinical Investigation</i> , 2001, 108, 1533-1540.	3.9	305
22	The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. <i>Blood Reviews</i> , 2014, 28, 221-226.	2.8	296
23	N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism. <i>Circulation</i> , 2005, 112, 1573-1579.	1.6	286
24	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	1.0	267
25	Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. <i>European Heart Journal</i> , 2020, 41, 522-529.	1.0	259
26	Management of Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 976-990.	1.2	258
27	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	1.2	258
28	Acute Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2008, 359, 2804-2813.	13.9	225
29	The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. <i>European Heart Journal</i> , 2019, 40, 3453-3455.	1.0	220
30	Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism. <i>Circulation</i> , 2011, 124, 2716-2724.	1.6	219
31	Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. <i>European Heart Journal</i> , 2006, 27, 386-392.	1.0	216
32	Leptin Promotes Vascular Remodeling and Neointimal Growth in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 112-117.	1.1	212
33	A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. <i>New England Journal of Medicine</i> , 2013, 369, 2304-2312.	13.9	210
34	Pulmonary embolism. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18028.	18.1	208
35	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
36	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205

#	ARTICLE	IF	CITATIONS
37	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. <i>European Respiratory Journal</i> , 2016, 48, 780-786.	3.1	199
38	CardioPulse. <i>European Heart Journal</i> , 2014, 35, 3145-3151.	1.0	192
39	Trends in mortality related to pulmonary embolism in the European Region, 2000â€“15: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respiratory Medicine</i> , 2020, 8, 277-287.	5.2	192
40	Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. <i>European Heart Journal</i> , 2011, 32, 1657-1663.	1.0	188
41	Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 44, 694-703.	3.1	186
42	Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. <i>European Heart Journal</i> , 2010, 31, 1836-1844.	1.0	183
43	Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. <i>European Respiratory Journal</i> , 2005, 25, 843-848.	3.1	179
44	Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2019, 40, 902-910.	1.0	179
45	Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. <i>FASEB Journal</i> , 2001, 15, 1840-1842.	0.2	166
46	Derivation and Validation of Multimarker Prognostication for Normotensive Patients with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 718-726.	2.5	164
47	Comparison of alteplase versus heparin for resolution of major pulmonary embolism. <i>American Journal of Cardiology</i> , 1998, 82, 966-970.	0.7	159
48	Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. <i>European Respiratory Journal</i> , 2016, 48, 1369-1376.	3.1	159
49	Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1018-1025.	2.5	158
50	Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice. <i>Circulation</i> , 2001, 103, 576-583.	1.6	155
51	Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. <i>Obesity</i> , 2013, 21, 461-468.	1.5	151
52	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
53	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 69-78.	0.8	140
54	Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 121-128.	1.9	129

#	ARTICLE	IF	CITATIONS
55	Elevated Heart-Type Fatty Acid-Binding Protein Levels on Admission Predict an Adverse Outcome in Normotensive Patients With Acute Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2150-2157.	1.2	126
56	Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 43, 1669-1677.	3.1	121
57	Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. <i>European Heart Journal</i> , 2006, 28, 224-229.	1.0	119
58	Thrombosis: A major contributor to global disease burden. <i>Thrombosis Research</i> , 2014, 134, 931-938.	0.8	119
59	Pulmonary embolism: risk assessment and management. <i>European Heart Journal</i> , 2012, 33, 3014-3022.	1.0	118
60	Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. <i>Thorax</i> , 2011, 66, 75-81.	2.7	115
61	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 "care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111
62	Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2020, 82, 29-37.	1.0	107
63	Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>American Heart Journal</i> , 2012, 163, 33-38.e1.	1.2	106
64	Global public awareness of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1365-1371.	1.9	106
65	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	1.0	106
66	Thrombosis: A Major Contributor to Global Disease Burden. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 724-735.	1.5	103
67	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-2018: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.	5.2	100
68	Leptin Enhances the Recruitment of Endothelial Progenitor Cells Into Neointimal Lesions After Vascular Injury by Promoting Integrin-Mediated Adhesion. <i>Circulation Research</i> , 2008, 103, 536-544.	2.0	92
69	Distinct antithrombotic consequences of platelet glycoprotein Ib α and VI deficiency in a mouse model of arterial thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2014-2021.	1.9	91
70	Multidetector CT Scan for Acute Pulmonary Embolism. <i>Chest</i> , 2012, 142, 1417-1424.	0.4	90
71	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89
72	Venous thromboembolism: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1219-1229.	1.8	88

#	ARTICLE	IF	CITATIONS
73	Inhibition of Endogenous Leptin Protects Mice From Arterial and Venous Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2196-2201.	1.1	86
74	Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2015, 148, 211-218.	0.4	85
75	Pulmonary embolism: impact of right ventricular dysfunction. <i>Current Opinion in Cardiology</i> , 2005, 20, 496-501.	0.8	83
76	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017, 38, ehw597.	1.0	83
77	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	1.0	83
78	Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2097-2103.	1.1	82
79	Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. <i>European Respiratory Journal</i> , 2015, 45, 201-210.	3.1	82
80	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. <i>European Heart Journal</i> , 2022, 43, 1033-1058.	1.0	80
81	Interferon lambda1/IL29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. <i>Journal of Pathology</i> , 2017, 243, 111-122.	2.1	79
82	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. <i>European Respiratory Journal</i> , 2018, 52, 1801687.	3.1	78
83	Different Mechanisms of Increased Luminal Stenosis After Arterial Injury in Mice Deficient for Urokinase- or Tissue-Type Plasminogen Activator. <i>Circulation</i> , 2002, 106, 1847-1852.	1.6	77
84	Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry. <i>European Respiratory Journal</i> , 2016, 47, 869-875.	3.1	77
85	Temporal Trends in the Prevalence of Infective Endocarditis in Germany Between 2005 and 2014. <i>American Journal of Cardiology</i> , 2017, 119, 317-322.	0.7	76
86	A Strategy Combining Imaging and Laboratory Biomarkers in Comparison With a Simplified Clinical Score for Risk Stratification of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2012, 141, 916-922.	0.4	75
87	Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 163, 46-55.	0.8	74
88	External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1164-1170.	1.8	71
89	Leptin Enhances the Potency of Circulating Angiogenic Cells Via Src Kinase and Integrin $\alpha 5$. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 200-206.	1.1	70
90	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. <i>European Heart Journal</i> , 2022, 43, 3387-3398.	1.0	69

#	ARTICLE	IF	CITATIONS
91	Possible Gender-Related Differences in the Risk-to-Benefit Ratio of Thrombolysis for Acute Submassive Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2007, 99, 103-107.	0.7	66
92	Comparison of risk assessment strategies for not-high-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 47, 1170-1178.	3.1	66
93	Exercise Training Reduces Neointimal Growth and Stabilizes Vascular Lesions Developing After Injury in Apolipoprotein Eâ€“Deficient Mice. <i>Circulation</i> , 2004, 109, 386-392.	1.6	64
94	Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2008, 31, 1024-1029.	3.1	62
95	Effects of Obesity and Weight Loss on the Functional Properties of Early Outgrowth Endothelial Progenitor Cells. <i>Journal of the American College of Cardiology</i> , 2010, 55, 357-367.	1.2	61
96	Patients with Lemierre syndrome have a high risk of new thromboembolic complications, clinical sequelae and death: an analysis of 712 cases. <i>Journal of Internal Medicine</i> , 2021, 289, 325-339.	2.7	61
97	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	1.2	59
98	Red blood cell distribution width â€“ a strong prognostic marker in cardiovascular disease â€“ is associated with cholesterol content of erythrocyte membrane. <i>Clinical Hemorheology and Microcirculation</i> , 2012, 51, 243-254.	0.9	57
99	Leptin-Dependent and Leptin-Independent Paracrine Effects of Perivascular Adipose Tissue on Neointima Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 980-987.	1.1	57
100	A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2014, 112, 996-1003.	1.8	56
101	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 4186-4195.	1.0	55
102	Venous Thromboembolism in COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1642-1653.	1.8	54
103	Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 312-320.	1.0	53
104	Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1436-1442.	1.9	53
105	From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. <i>Thrombosis and Haemostasis</i> , 2017, 117, 769-783.	1.8	53
106	The Right Ventricle in Health and Disease: Insights into Physiology, Pathophysiology and Diagnostic Management. <i>Cardiology</i> , 2012, 121, 263-273.	0.6	52
107	Non-invasive imaging in the diagnosis of acute viral myocarditis. <i>Clinical Research in Cardiology</i> , 2009, 98, 753-763.	1.5	51
108	A simple score for rapid risk assessment of non-high-risk pulmonary embolism. <i>Clinical Research in Cardiology</i> , 2013, 102, 73-80.	1.5	51

#	ARTICLE	IF	CITATIONS
109	Anticoagulant-related gastrointestinal bleeding“ could this facilitate early detection of benign or malignant gastrointestinal lesions?. <i>Annals of Medicine</i> , 2014, 46, 672-678.	1.5	51
110	External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Thrombosis Research</i> , 2015, 135, 796-801.	0.8	50
111	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 600-609.	1.0	50
112	The Prothrombotic Effects of Leptin. <i>Annals of the New York Academy of Sciences</i> , 2001, 947, 134-142.	1.8	49
113	Differences between perivascular adipose tissue surrounding the heart and the internal mammary artery: possible role for the leptin-inflammation-fibrosis-hypoxia axis. <i>Clinical Research in Cardiology</i> , 2016, 105, 887-900.	1.5	48
114	Submassive and Massive Pulmonary Embolism: A Target for Thrombolytic Therapy?. <i>Thrombosis and Haemostasis</i> , 1999, 82, 104-108.	1.8	47
115	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	0.8	47
116	The Diagnosis and Treatment of Acute Pulmonary Embolism. <i>Deutsches A&#x0308;rztblatt International</i> , 2010, 107, 589-95.	0.6	47
117	Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNF± involvement. <i>Thrombosis Research</i> , 2008, 122, 366-375.	0.8	45
118	Mobile thrombi in atherosclerotic lesions of the thoracic aorta: The diagnostic impact of transesophageal echocardiography. <i>American Heart Journal</i> , 1993, 126, 707-710.	1.2	44
119	Adipokines and thrombosis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 864-871.	0.9	44
120	Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. <i>Cardiovascular Research</i> , 2012, 93, 170-180.	1.8	44
121	Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity. <i>Journal of Translational Medicine</i> , 2013, 11, 170.	1.8	44
122	Incomplete echocardiographic recovery at 6Âmonths predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	1.5	44
123	Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: A Meta-Analysis. <i>Current Vascular Pharmacology</i> , 2018, 16, 179-189.	0.8	43
124	Sexâ€specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 151-161.	1.9	42
125	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1248-1263.	0.8	40
126	Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism. <i>Resuscitation</i> , 2022, 170, 285-292.	1.3	40

#	ARTICLE	IF	CITATIONS
127	Do PAI-1 and Vitronectin Promote or Inhibit Neointima Formation?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1943-1945.	1.1	39
128	Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. <i>Thrombosis and Haemostasis</i> , 2005, 93, 145-152.	1.8	39
129	Validation of a New Risk Score to Predict Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1487-1493.	0.7	39
130	Quality of life and functional limitations after pulmonary embolism and its prognostic relevance. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1923-1934.	1.9	39
131	Thrombolysis in submassive pulmonary embolism? Yes. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1127-1129.	1.9	38
132	Effects of Exercise Training on the Severity and Composition of Atherosclerotic Plaque in apoE-Deficient Mice. <i>Journal of Vascular Research</i> , 2011, 48, 347-356.	0.6	38
133	Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin. <i>European Respiratory Journal</i> , 2015, 46, 1701-1710.	3.1	38
134	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, 191-197.	1.8	38
135	Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. <i>European Respiratory Journal</i> , 2018, 51, 1701775.	3.1	38
136	Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: five-year German national patient sample including 13,575 implants. <i>EuroIntervention</i> , 2019, 14, 1725-1732.	1.4	38
137	Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e585-e593.	2.2	38
138	Leptin signalling and leptin-mediated activation of human platelets: Importance of JAK2 and the phospholipases CÎ²2 and A2. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1063-1071.	1.8	37
139	Leptin promotes neointima formation and smooth muscle cell proliferation via NADPH oxidase activation and signalling in caveolin-rich microdomains. <i>Cardiovascular Research</i> , 2013, 99, 555-565.	1.8	37
140	Lysed Erythrocyte Membranes Promote Vascular Calcification. <i>Circulation</i> , 2019, 139, 2032-2048.	1.6	37
141	Activated Endothelial TGFÎ²1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1. <i>Circulation Research</i> , 2020, 126, 162-181.	2.0	37
142	Overexpression of Integrin Î²5 Enhances the Paracrine Properties of Circulating Angiogenic Cells via Src Kinase-Mediated Activation of STAT3. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1398-1406.	1.1	36
143	Is it time for home treatment of pulmonary embolism?. <i>European Respiratory Journal</i> , 2012, 40, 742-749.	3.1	36
144	Validation of a fast prognostic score for risk stratification of normotensive patients with acute pulmonary embolism. <i>Clinical Research in Cardiology</i> , 2020, 109, 1008-1017.	1.5	36

#	ARTICLE	IF	CITATIONS
145	Endothelial Leptin Receptor Deletion Promotes Cardiac Autophagy and Angiogenesis Following Pressure Overload by Suppressing Akt/mTOR Signaling. <i>Circulation: Heart Failure</i> , 2019, 12, e005622.	1.6	35
146	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate- to High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	1.8	35
147	Expression of the leptin receptor in different types of vascular lesions. <i>Histochemistry and Cell Biology</i> , 2007, 128, 323-333.	0.8	34
148	Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1123-1129.	1.8	34
149	Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2015, 45, 1323-1331.	3.1	34
150	Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism. <i>Chest</i> , 2021, 159, 2428-2438.	0.4	34
151	Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 209, 94-98.	0.8	34
152	Leptin Locally Synthesized in Carotid Atherosclerotic Plaques Could Be Associated With Lesion Instability and Cerebral Emboli. <i>Journal of the American Heart Association</i> , 2012, 1, e001727.	1.6	32
153	Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 250-258.	0.3	32
154	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2019, 173, 166-171.	0.8	32
155	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
156	Thrombolysis for pulmonary embolism: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2010, 103, 877-883.	1.8	30
157	Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. <i>Thrombosis and Haemostasis</i> , 2016, 115, 827-834.	1.8	30
158	Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study. <i>European Respiratory Journal</i> , 2018, 51, 1702037.	3.1	30
159	Survival Benefit of Obese Patients With Pulmonary Embolism. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1960-1973.	1.4	30
160	Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2019, 39, 076-086.	0.9	30
161	Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1143-1146.	1.8	30
162	Desmoteplase in acute massive pulmonary thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 557-562.	1.8	29

#	ARTICLE	IF	CITATIONS
163	Venous thromboembolism: A Call for risk assessment in all hospitalised patients. <i>Thrombosis and Haemostasis</i> , 2016, 116, 777-779.	1.8	29
164	Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?. <i>Thrombosis and Haemostasis</i> , 2016, 115, 233-235.	1.8	29
165	Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample. <i>Viruses</i> , 2022, 14, 275.	1.5	29
166	Thrombosis: A major contributor to global disease burden. <i>Thrombosis and Haemostasis</i> , 2014, 112, 843-852.	1.8	28
167	Should Thrombolytic Therapy Be Used in Patients with Pulmonary Embolism?. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 69-74.	1.0	27
168	Fibrinolysis for Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 371, 579-582.	13.9	27
169	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	1.9	27
170	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12520.	1.0	27
171	Long-term impact of acute kidney injury on prognosis in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 283, 48-54.	0.8	27
172	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27
173	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 787-794.	0.2	26
174	Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis. <i>Scientific Reports</i> , 2017, 7, 4591.	1.6	26
175	History of deep vein thrombosis is a discriminator for concomitant atrial fibrillation in pulmonary embolism. <i>Thrombosis Research</i> , 2015, 136, 899-906.	0.8	25
176	Plasminogen Activator Inhibitor-1 From Bone Marrow-Derived Cells Suppresses Neointimal Formation After Vascular Injury in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1254-1259.	1.1	24
177	The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 140-148.	1.8	24
178	In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 258-264.	0.4	24
179	Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina—The role of GNB3 C825T polymorphism. <i>American Heart Journal</i> , 2006, 151, 870-877.	1.2	23
180	Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. <i>Atherosclerosis</i> , 2009, 205, 63-73.	0.4	23

#	ARTICLE	IF	CITATIONS
181	Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 62-71.	0.8	23
182	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	1.3	23
183	A five-year, single-centre experience on ultrasound-assisted, catheter-directed thrombolysis in patients with pulmonary embolism at high risk and intermediate to high risk. <i>EuroIntervention</i> , 2018, 14, 1136-1143.	1.4	23
184	Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism. <i>Critical Care Clinics</i> , 2011, 27, 953-967.	1.0	22
185	Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism – results from clinical observation studies. <i>EBioMedicine</i> , 2020, 60, 102978.	2.7	22
186	Traps N' Clots: NET-Mediated Thrombosis and Related Diseases. <i>Thrombosis and Haemostasis</i> , 2020, 120, 373-383.	1.8	22
187	Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 471-480.	1.3	21
188	Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 197, 48-55.	0.8	21
189	Risk stratification of normotensive pulmonary embolism based on the sPESI – Does it work for all patients?. <i>International Journal of Cardiology</i> , 2015, 197, 162-163.	0.8	21
190	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456.	1.0	21
191	Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 098-101.	1.8	21
192	Massive Pulmonary Embolism: What Level of Aggression?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 047-055.	0.8	20
193	Diagnosis of early myocarditis after respiratory or gastrointestinal tract viral infection: insights from cardiovascular magnetic resonance. <i>Clinical Research in Cardiology</i> , 2010, 99, 707-714.	1.5	20
194	Effect of smoking cessation on the number and adhesive properties of early outgrowth endothelial progenitor cells. <i>International Journal of Cardiology</i> , 2011, 152, 61-69.	0.8	20
195	Usefulness of Matrix Metalloproteinase-9 Plasma Levels to Identify Patients With Preserved Left Ventricular Systolic Function After Acute Myocardial Infarction Who Could Benefit from Eplerenone. <i>American Journal of Cardiology</i> , 2012, 110, 1085-1091.	0.7	20
196	Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't. <i>European Respiratory Journal</i> , 2021, 58, 2101111.	3.1	20
197	Cigarette Smoke Exposure Promotes Arterial Thrombosis and Vessel Remodeling after Vascular Injury in Apolipoprotein E-Deficient Mice. <i>Journal of Vascular Research</i> , 2008, 45, 480-492.	0.6	19
198	Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: Modulatory effects of rosuvastatin. <i>International Journal of Cardiology</i> , 2013, 170, 173-181.	0.8	19

#	ARTICLE	IF	CITATIONS
199	Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project. <i>BMJ Open</i> , 2015, 5, e008157.	0.8	19
200	Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism. <i>International Journal of Cardiology</i> , 2019, 290, 144-149.	0.8	19
201	Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice. <i>Thrombosis and Haemostasis</i> , 2007, 98, 220-227.	1.8	18
202	Acute pulmonary embolism revisited. <i>Postgraduate Medical Journal</i> , 2008, 84, 651-658.	0.9	18
203	Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 417-424.	2.8	18
204	Differential Effect of Baseline Adiponectin on All-Cause Mortality in Hemodialysis Patients Depending on Initial Body Mass Index. Long-Term Follow-Up Data of 4.5 Years. , 2013, 23, 45-56.		18
205	Risk-adapted management of pulmonary embolism. <i>Thrombosis Research</i> , 2017, 151, S92-S96.	0.8	18
206	Perivascular adipose tissue: epiphenomenon or local risk factor?. <i>International Journal of Obesity</i> , 2017, 41, 1311-1323.	1.6	18
207	Sex-specific differences in the distal versus proximal presenting location of acute deep vein thrombosis. <i>Thrombosis Research</i> , 2018, 172, 74-79.	0.8	18
208	Fatality rates and use of systemic thrombolysis in pregnant women with pulmonary embolism. <i>ESC Heart Failure</i> , 2020, 7, 2365-2372.	1.4	18
209	Treatment of the antiphospholipid syndrome with direct oral anticoagulants. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 483-486.	0.6	18
210	Mechanisms Linking Leptin to Arterial and Venous Thrombosis: Potential Pharmacological Targets. <i>Current Pharmaceutical Design</i> , 2014, 20, 635-640.	0.9	18
211	Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2290-2295.	1.9	17
212	Thrombolytic therapy for submassive pulmonary embolism. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 379-389.	0.7	17
213	Trends in Pulmonary Embolism Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 171-173.	1.2	17
214	Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 056-065.	0.8	17
215	Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2019, 9, 7145.	1.6	17
216	Temporal trends in management and outcome of pulmonary embolism: a single-centre experience. <i>Clinical Research in Cardiology</i> , 2020, 109, 67-77.	1.5	17

#	ARTICLE	IF	CITATIONS
217	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	3.1	17
218	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421.	1.9	17
219	Cerebral and Renal Embolization after Lymphography in a Patient with Non-Hodgkin Lymphoma: Case Report. <i>Radiology</i> , 1999, 210, 381-383.	3.6	16
220	Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 622-628.	0.8	16
221	The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice. <i>Blood Advances</i> , 2018, 2, 1300-1314.	2.5	16
222	Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area. <i>Thrombosis Research</i> , 2022, 212, 44-50.	0.8	16
223	Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented macrophage density. <i>Journal of Vascular Surgery</i> , 2008, 48, 1146-1155.	0.6	15
224	Sex-specific differences in pulmonary embolism. <i>Thrombosis Research</i> , 2019, 178, 173-181.	0.8	15
225	Recurrence Risk after First Symptomatic Distal versus Proximal Deep Vein Thrombosis According to Baseline Risk Factors. <i>TH Open</i> , 2019, 03, e58-e63.	0.7	15
226	A review of venous thromboembolism in COVID-19: A clinical perspective. <i>Clinical Respiratory Journal</i> , 2021, 15, 506-512.	0.6	15
227	Venous lactate improves the prediction of in-hospital adverse outcomes in normotensive pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2021, 86, 25-31.	1.0	15
228	Management of intermediate-risk pulmonary embolism: uncertainties and challenges. <i>European Journal of Haematology</i> , 2015, 95, 489-497.	1.1	14
229	Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go. <i>European Journal of Heart Failure</i> , 2016, 18, 1129-1131.	2.9	14
230	Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism. <i>European Respiratory Journal</i> , 2018, 51, 1800077.	3.1	14
231	Diagnosis of recurrent venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 229-235.	0.8	14
232	A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolic project (GMP-VTE). <i>Thrombosis Research</i> , 2019, 181, 84-91.	0.8	14
233	Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease. <i>European Respiratory Journal</i> , 2021, 58, 2004196.	3.1	14
234	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00719-2020.	1.1	14

#	ARTICLE	IF	CITATIONS
235	Role of Cardiac Ultrasound in the Detection of Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1996, 17, 39-49.	0.8	13
236	Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice. <i>Thrombosis Research</i> , 2012, 130, 793-798.	0.8	13
237	Reduction of the radiation dose received by interventional cardiologists following training in radiation protection. <i>Radiation Protection Dosimetry</i> , 2013, 155, 119-121.	0.4	13
238	Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: Results From a Single-Center Cohort. <i>Angiology</i> , 2017, 68, 433-440.	0.8	13
239	Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1332-1346.	1.8	13
240	Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism. <i>Clinics in Chest Medicine</i> , 2010, 31, 759-769.	0.8	12
241	Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure. <i>Quality of Life Research</i> , 2012, 21, 143-153.	1.5	12
242	BMI-independent inverse relationship of plasma leptin levels with outcome in patients with acute pulmonary embolism. <i>International Journal of Obesity</i> , 2013, 37, 204-210.	1.6	12
243	Increased Lymphangiogenesis and Lymphangiogenic Growth Factor Expression in Perivascular Adipose Tissue of Patients with Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1000.	1.0	12
244	Atrial fibrillation is frequent but does not affect risk stratification in pulmonary embolism. <i>Journal of Internal Medicine</i> , 2020, 287, 100-113.	2.7	12
245	Age-Dependent and -Independent Effects of Perivascular Adipose Tissue and Its Paracrine Activities during Neointima Formation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 282.	1.8	12
246	Definition of tachycardia for risk stratification of pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2020, 82, 76-82.	1.0	12
247	Temporal trends and predictors of inhospital death in patients hospitalised for heart failure in Germany. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 990-997.	0.8	12
248	Severe Hemorrhage Associated With Oral Anticoagulants. <i>Deutsches Arzteblatt International</i> , 2020, 117, 312-319.	0.6	12
249	Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 1330.	0.4	11
250	Lipid apheresis improves microcirculation of the upper limbs. <i>Journal of Clinical Apheresis</i> , 2011, 26, 167-173.	0.7	11
251	Management of pulmonary embolism: recent evidence and the new European guidelines. <i>European Respiratory Journal</i> , 2014, 44, 1385-1390.	3.1	11
252	Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 364-371.	1.0	11

#	ARTICLE	IF	CITATIONS
253	EkoSonic [®] endovascular system and other catheter-directed treatment reperfusion strategies for acute pulmonary embolism: overview of efficacy and safety outcomes. <i>Expert Review of Medical Devices</i> , 2020, 17, 739-749.	1.4	11
254	Isolated Pulmonary Embolism Is Associated With a High Risk of Arterial Thrombotic Disease. <i>Chest</i> , 2020, 158, 341-349.	0.4	11
255	Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. <i>Blood</i> , 2021, 137, 2681-2693.	0.6	11
256	Outcome of patients with different clinical presentations of high-risk pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 787-796.	0.4	11
257	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021, 8, e627-e636.	2.2	11
258	A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. <i>Pharmacogenomics</i> , 2017, 18, 23-34.	0.6	10
259	Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism. <i>ESC Heart Failure</i> , 2020, 7, 4061-4070.	1.4	10
260	Management of acute pulmonary embolism 2019: what is new in the updated European guidelines?. <i>Internal and Emergency Medicine</i> , 2020, 15, 957-966.	1.0	10
261	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. <i>European Journal of Internal Medicine</i> , 2021, 88, 43-51.	1.0	10
262	In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis. <i>Thrombosis Research</i> , 2021, 203, 82-84.	0.8	10
263	Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolism. <i>Journal of Diabetes Investigation</i> , 2022, 13, 725-737.	1.1	10
264	The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism. <i>Thrombosis Research</i> , 2013, 132, 543-547.	0.8	9
265	Progress in the management of acute pulmonary embolism. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 417-424.	1.2	9
266	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2425-2434.	1.8	9
267	Absence of transforming growth factor beta 1 in murine platelets reduces neointima formation without affecting arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1782-1797.	1.8	9
268	Global public awareness about atrial fibrillation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 49-57.	1.0	9
269	Magnetic resonance direct thrombus imaging for pre-operative assessment of acute thrombosis in chronic thromboembolic pulmonary hypertension. <i>European Heart Journal</i> , 2019, 40, 944-944.	1.0	9
270	Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precapillary pulmonary hypertension: A cardiac magnetic resonance study. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 112-117.	0.4	9

#	ARTICLE	IF	CITATIONS
271	Risk factors for chronic thromboembolic pulmonary hypertension – Importance of thyroid disease and function. <i>Thrombosis Research</i> , 2020, 185, 20-26.	0.8	9
272	Uncertain Value of High-sensitive Troponin T for Selecting Patients With Acute Pulmonary Embolism for Outpatient Treatment by Hestia Criteria. <i>Academic Emergency Medicine</i> , 2020, 27, 1043-1046.	0.8	9
273	Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA. <i>Thrombosis and Haemostasis</i> , 2006, 95, 857-864.	1.8	9
274	Venous thromboembolism in patients hospitalized for knee joint replacement surgery. <i>Scientific Reports</i> , 2020, 10, 22440.	1.6	9
275	Update on the cardiovascular risk in obesity: endocrine and paracrine role of the adipose tissue. <i>Hellenic Journal of Cardiology</i> , 2011, 52, 327-36.	0.4	9
276	C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction. <i>BMC Nephrology</i> , 2017, 18, 202.	0.8	8
277	Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques. <i>Thrombosis Research</i> , 2018, 164, 163-169.	0.8	8
278	What's new in severe pulmonary embolism?. <i>Intensive Care Medicine</i> , 2019, 45, 75-77.	3.9	8
279	Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) Trial. <i>European Respiratory Journal</i> , 2020, 56, 2000663.	3.1	8
280	Venous thromboembolism in patients hospitalized for hip joint replacement surgery. <i>Thrombosis Research</i> , 2020, 190, 1-7.	0.8	8
281	Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A. <i>Rheumatology</i> , 2021, 60, 1300-1312.	0.9	8
282	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <i>European Heart Journal</i> , 2022, 43, 940-958.	1.0	8
283	Time trends of pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-9.	0.8	8
284	Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12509.	1.0	8
285	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. <i>Thrombosis and Haemostasis</i> , 2022, 122, 552-559.	1.8	8
286	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1255-1268.	0.7	8
287	Noninvasive estimation of right ventricular systolic pressure in postinfarction ventricular septal rupture. <i>Critical Care Medicine</i> , 1997, 25, 1167-1174.	0.4	8
288	Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1063-71.	1.8	8

#	ARTICLE	IF	CITATIONS
289	Impact of Systemic Atherosclerosis on Clinical Characteristics and Short-Term Outcomes in Patients with Deep Venous Thrombosis or Thrombophlebitis. <i>American Journal of the Medical Sciences</i> , 2022, 363, 232-241.	0.4	7
290	Theme 4: Invasive management of (recurrent) VTE and PTS. <i>Thrombosis Research</i> , 2015, 136, S19-S25.	0.8	6
291	The Elusive Evidence for Inferior Vena Cava Filters to Prevent Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1598-1600.	1.2	6
292	Detection and treatment of chronic thromboembolic pulmonary hypertension: Still a lot of homework to do. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 24-25.	0.4	6
293	Sex-specific and age-related seasonal variations regarding incidence and in-hospital mortality of pulmonary embolism in Germany. <i>ERJ Open Research</i> , 2020, 6, 00181-2020.	1.1	6
294	Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. <i>ERJ Open Research</i> , 2020, 6, 00356-2020.	1.1	6
295	Thrombosis and thromboembolism related to COVID-19: A clarion call for obtaining solid estimates from large-scale multicenter data. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 741-743.	1.0	6
296	Pulmonary Embolism and Pregnancy—Challenges in Diagnostic and Therapeutic Decisions in High-Risk Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856594.	1.1	6
297	Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2022, 42, 261-267.	0.9	6
298	The case for thrombolysis in acute major pulmonary embolism: hemodynamic benefits and beyond. <i>Intensive Care Medicine</i> , 2002, 28, 1547-1551.	3.9	5
299	Large emboli on their way through the heart – First live demonstration of large paradoxical embolisms through a patent foramen ovale. <i>European Journal of Echocardiography</i> , 2007, 8, 158-160.	2.3	5
300	Thrombolysis for hemodynamically stable patients with pulmonary embolism: Still searching for the intermediate-risk group. <i>Thrombosis Research</i> , 2009, 124, 647-648.	0.8	5
301	Asthma and pulmonary embolism: bringing airways and vessels closer together. <i>European Respiratory Journal</i> , 2014, 43, 694-696.	3.1	5
302	Acute phase treatment of venous thromboembolism: advanced therapy. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1202-1209.	1.8	5
303	Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the Strategic Reperfusion Early After Myocardial Infarction (STREAM) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
304	Impact of obesity on adverse in-hospital outcomes in patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip® procedure - Results from the German nationwide inpatient sample. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1365-1374.	1.1	5
305	Hellenic Registry on Myocarditis SyndromES on behalf of Hellenic Heart Failure Association: The HERMES-HF Registry. <i>ESC Heart Failure</i> , 2020, 7, 3676-3684.	1.4	5
306	Thrombosis and Thromboembolism Related to COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 1388-1390.	0.3	5

#	ARTICLE	IF	CITATIONS
307	Chronic thromboembolic disease following pulmonary embolism: more work ahead. <i>European Respiratory Journal</i> , 2020, 55, 2000229.	3.1	5
308	Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. <i>Heart</i> , 2021, 107, 549-555.	1.2	5
309	Reversal of cardiopulmonary exercise intolerance in patients with post-thrombotic obstruction of the inferior vena cava. <i>Thrombosis Research</i> , 2021, 208, 219-225.	0.8	5
310	Prevalence of pulmonary embolism in 127,945 autopsies performed in cancer patients in the United States between 2003 and 2019. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1591-1593.	1.9	5
311	Acute Pulmonary Embolism: Its Diagnosis and Treatment From a Multidisciplinary Viewpoint. <i>Deutsches Ärzteblatt International</i> , 2021, , .	0.6	5
312	Where to treat patients with acute pulmonary embolism?. <i>Kardiologia Polska</i> , 2020, 78, 15-19.	0.3	5
313	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. <i>Respiration</i> , 2022, 101, 307-320.	1.2	5
314	PAI-1 and vasculopathy: the debate continues. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 13-15.	1.9	4
315	Prolactin as a modulator of platelet function and thrombosis: The end of the story, or a new beginning?. <i>Thrombosis and Haemostasis</i> , 2009, 101, 991-992.	1.8	4
316	Tenecteplase can be given to patients with intermediate-risk pulmonary embolism – But should it?. <i>Thrombosis Research</i> , 2010, 126, e407-e408.	0.8	4
317	Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk. <i>Journal of Clinical Apheresis</i> , 2014, 29, 235-242.	0.7	4
318	Risk-Adapted Management of Acute Pulmonary Embolism: Recent Evidence, New Guidelines. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0040.	0.4	4
319	Novel echocardiographic prognostic markers for cardiac tamponade in patients with large malignant pericardial effusions: A paradigm shift from flow to tissue imaging. <i>Echocardiography</i> , 2017, 34, 1315-1323.	0.3	4
320	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 128-131.	0.8	4
321	Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme. <i>Hamostaseologie</i> , 2019, 39, 117-127.	0.9	4
322	Increased interest in acute pulmonary embolism in Italy during the COVID-19 pandemic: a google trends-based analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 92-94.	1.0	4
323	2019 ESC guidelines on pulmonary embolism: Novelties and unanswered questions. <i>European Journal of Internal Medicine</i> , 2020, 74, 1-4.	1.0	4
324	Prognostic value of right atrial dilation in patients with pulmonary embolism. <i>ERJ Open Research</i> , 2021, 7, 00414-2020.	1.1	4

#	ARTICLE	IF	CITATIONS
325	Homoarginine and methylarginines independently predict long-term outcome in patients presenting with suspicion of venous thromboembolism. <i>Scientific Reports</i> , 2021, 11, 9569.	1.6	4
326	Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 343, 114-121.	0.8	4
327	Acute Phase Treatment of Pulmonary Embolism. <i>Current Vascular Pharmacology</i> , 2014, 12, 393-400.	0.8	4
328	Pulmonary embolism hotline 2012. <i>Hamostaseologie</i> , 2013, 33, 43-50.	0.9	4
329	Diagnosis of pulmonary embolism: progress after many YEARS. <i>Lancet, The</i> , 2017, 390, 210-211.	6.3	3
330	Pulmonary Embolism: Contemporary Medical Management and Future Perspectives. <i>Annals of Vascular Diseases</i> , 2018, 11, 265-276.	0.2	3
331	Therapeutic Advances in Emergency Cardiology: Acute Pulmonary Embolism. <i>American Journal of Therapeutics</i> , 2019, 26, e248-e256.	0.5	3
332	Home treatment of pulmonary embolism: are all the questions answered now after the HOME-PE trial?. <i>Cardiovascular Research</i> , 2020, 116, e179-e181.	1.8	3
333	Management of Pulmonary Embolism: Results from the German Chest Pain Unit Registry. <i>Cardiology</i> , 2021, 146, 304-310.	0.6	3
334	Colocalization of Erythrocytes and Vascular Calcification in Human Atherosclerosis: A Systematic Histomorphometric Analysis. <i>TH Open</i> , 2021, 05, e113-e124.	0.7	3
335	Sex differences in Lemierre syndrome: Individual patient-level analysis. <i>Thrombosis Research</i> , 2021, 202, 36-39.	0.8	3
336	A targeted proteomics investigation of the obesity paradox in venous thromboembolism. <i>Blood Advances</i> , 2021, 5, 2909-2918.	2.5	3
337	High-sensitivity troponin I for risk stratification in normotensive pulmonary embolism. <i>ERJ Open Research</i> , 2020, 6, 00625-2020.	1.1	3
338	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008â€“2019: Retrospective analysis of epidemiological data. <i>Thrombosis Research</i> , 2022, 209, 41-46.	0.8	3
339	Variation of platelet function in clinical phenotypes of acute venous thromboembolism â€“ Results from the GMPâ€VTE project. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 705-715.	1.9	3
340	Impact of thyroid dysfunction on short-term outcomes and long-term mortality in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2022, 211, 70-78.	0.8	3
341	High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 994-1002.	0.4	3
342	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. <i>Neurological Research and Practice</i> , 2022, 4, 16.	1.0	3

#	ARTICLE	IF	CITATIONS
343	EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia. <i>JCI Insight</i> , 2022, 7, .	2.3	3
344	A New Method to Diagnose Pulmonary Embolism: David against Goliath(s). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 626-627.	2.5	2
345	Impact of World Thrombosis Day campaign. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 138-141.	1.0	2
346	Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 183-190.	0.3	2
347	Response to "Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonary angiography sufficient?" TM . <i>European Heart Journal</i> , 2019, 40, 3357-3358.	1.0	2
348	ABO691...INCREASED CARDIOVASCULAR RISK IN MIXED CONNECTIVE TISSUE DISEASE: EVALUATION OF MACROVASCULAR INVOLVEMENT AND ITS PREDICTORS BY AORTIC PULSE WAVE VELOCITY. , 2019, , .		2
349	The optimal imaging test for diagnosis of acute pulmonary embolism: a second chance for lung scintigraphy?. <i>European Respiratory Journal</i> , 2020, 55, 2001426.	3.1	2
350	Autoimmune reactivity is present in patients with incident coronary artery ectasia. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 733-735.	0.3	2
351	COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report. <i>Hamostaseologie</i> , 2021, , .	0.9	2
352	Accidental left ventricular placement of a defibrillator probe due to a patent foramen ovale in arrhythmogenic right ventricular dysplasia. <i>Acta Cardiologica</i> , 2004, 59, 449-451.	0.3	2
353	Catheter-directed thrombolysis for acute pulmonary embolism: Where do we stand?. <i>Lung India</i> , 2017, 34, 221.	0.3	2
354	Recurrent venous thromboembolism: Quite harmless after all?. <i>Thrombosis and Haemostasis</i> , 2008, 99, 655-656.	1.8	1
355	Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. <i>Clinical Research in Cardiology Supplements</i> , 2013, 8, 38-45.	2.0	1
356	Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies. <i>Hamostaseologie</i> , 2020, 40, 679-686.	0.9	1
357	Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. <i>European Respiratory Journal</i> , 2020, 55, 1902323.	3.1	1
358	The right ventricle revisited. <i>Hellenic Journal of Cardiology</i> , 2013, 54, 419-21.	0.4	1
359	Thrombolytic Treatment of Acute Pulmonary Embolism: Toward the End of a Long-Lasting Debate?. , 2005, , 13-22.		0
360	COMPARISON OF CIN RISK PREDICTION MODELS: A PROSPECTIVE COHORT STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1363.	1.2	0

#	ARTICLE	IF	CITATIONS
361	Medical Management of Pulmonary Embolism. , 2018, , 371-387.		0
362	Diagnosis of Cerebral Venous Thrombosis: The Complementary Value of Imaging Methods. Thrombosis and Haemostasis, 2018, 118, 956-956.	1.8	0
363	The Membership Committee of the ESC. Cardiovascular Research, 2019, 115, e130-e132.	1.8	0
364	Center for Thrombosis and Hemostasis Mainz. European Heart Journal, 2019, 40, 1827-1829.	1.0	0
365	Power of the Wilcoxonâ€“Mannâ€“Whitney test for nonâ€“inferiority in the presence of deathâ€“censored observations. Biometrical Journal, 2019, 61, 1187-1200.	0.6	0
366	Letter by Tziakas et al Regarding Article, â€œAortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targetsâ€“ Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e180-e181.	1.1	0
367	Predicting Venous Thromboembolism in Primary Care. Thrombosis and Haemostasis, 2020, 120, 531-533.	1.8	0
368	Thrombolytic treatment of pulmonary embolism: Life-saving option or unacceptable risk?. , 2000, , 183-191.		0
369	Exercise Training Leads To A significant Reduction In Luminal Stenosis And Neointimal Formation After Vascular Injury In Apolipoprotein E-deficient Mice. Medicine and Science in Sports and Exercise, 2004, 36, S22.	0.2	0
370	Risikostratifikation und differenzierte Therapiekonzepte auf der Intensivstation bei Patienten mit akuter Lungenembolie. , 2008, , 84-92.		0
371	Fibrinolysis for Pulmonary Embolism. , 2010, , 351-361.		0
372	Contemporary Diagnostic Algorithm for the Hemodynamically Unstable Patient With Suspected Massive Pulmonary Embolism. , 2007, , 105-108.		0
373	Modulators of Nitric Oxide-Dependent Osteoinductive Activity of Human Red Blood Cells. TH Open, 0, , .	0.7	0